{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,26]],"date-time":"2026-04-26T03:54:58Z","timestamp":1777175698765,"version":"3.51.4"},"reference-count":61,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,12,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The BCR-ABL-negative myeloproliferative neoplasms (MPNs) have a variable risk of progressing to accelerated- or blast-phase MPN (MPN-AP\/MPN-BP), defined by the presence of 10% to 19% and more than or equal to 20% myeloid blasts in the peripheral blood or bone marrow, respectively. The molecular processes underlying the progression to MPN-AP\/MPN-BP are becoming increasingly understood with the acquisition of additional mutations in epigenetic modifiers (eg, ASXL1, EZH2, TET2), TP53, the Ras pathway, or splicing factors (eg, SRSF2, U2AF1), having been described as important steps in this evolutionary process. At least partially driven by the enrichment of these high-risk molecular features, the prognosis of patients with MPN-BP remains inferior to other patients with acute myeloid leukemia, with a median overall survival of 3 to 6 months. Allogeneic hematopoietic cell transplantation remains the only potentially curative therapeutic modality, but only a minority of patients are eligible. In the absence of curative intent, therapeutic strategies or palliative treatment with hypomethylating agents as monotherapy or in combination with ruxolitinib or venetoclax can be considered. Several novel agents are in various stages of clinical development but are not available for routine use at this point, highlighting the need for ongoing research and the prioritization of clinical trial enrollment when feasible.<\/jats:p>","DOI":"10.1182\/hematology.2022000341","type":"journal-article","created":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T16:09:13Z","timestamp":1670602153000},"page":"218-224","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":8,"title":["Hitting the brakes on accelerated and blast-phase myeloproliferative neoplasms: current and emerging concepts"],"prefix":"10.1182","volume":"2022","author":[{"given":"Jan Philipp","family":"Bewersdorf","sequence":"first","affiliation":[{"name":"Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raajit K.","family":"Rampal","sequence":"additional","affiliation":[{"name":"Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2022,12,9]]},"reference":[{"issue":"20","key":"2022120916075589200_hem2022000341C1","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"22","key":"2022120916075589200_hem2022000341C2","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1182\/blood-2018-03-785907","article-title":"How I treat the blast phase of Philadelphia chromosome\u2013 negative myeloproliferative neoplasms","volume":"132","author":"Odenike","year":"2018","journal-title":"Blood"},{"issue":"5","key":"2022120916075589200_hem2022000341C3","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1159\/000512929","article-title":"Accelerated phase of myeloproliferative neoplasms","volume":"144","author":"Shahin","year":"2021","journal-title":"Acta Haematol"},{"issue":"5","key":"2022120916075589200_hem2022000341C4","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/s41375-018-0019-y","article-title":"Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts","volume":"32","author":"Tefferi","year":"2018","journal-title":"Leukemia"},{"issue":"July","key":"2022120916075589200_hem2022000341C5","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.leukres.2018.05.004","article-title":"Outcomes and predictors of survival in blast phase myeloproliferative neoplasms","volume":"70","author":"Lancman","year":"2018","journal-title":"Leuk Res"},{"issue":"5","key":"2022120916075589200_hem2022000341C6","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1182\/blood-2008-02-138230","article-title":"The natural history and treatment outcome of blast phase BCR-ABL-myeloproliferative neoplasms","volume":"112","author":"Tam","year":"2008","journal-title":"Blood"},{"issue":"9","key":"2022120916075589200_hem2022000341C7","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N Engl J Med"},{"issue":"7","key":"2022120916075589200_hem2022000341C8","doi-asserted-by":"crossref","first-page":"e317","DOI":"10.1016\/S2352-3026(17)30088-1","article-title":"Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study","volume":"4","author":"Harrison","year":"2017","journal-title":"Lancet Haematol"},{"issue":"5","key":"2022120916075589200_hem2022000341C9","doi-asserted-by":"crossref","first-page":"e225","DOI":"10.1016\/S2352-3026(17)30027-3","article-title":"Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial","volume":"4","author":"Mesa","year":"2017","journal-title":"Lancet Haematol"},{"issue":"3","key":"2022120916075589200_hem2022000341C10","doi-asserted-by":"crossref","first-page":"e196","DOI":"10.1016\/S2352-3026(19)30236-4","article-title":"Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study","volume":"7","author":"Gisslinger","year":"2020","journal-title":"Lancet Haematol"},{"issue":"16","key":"2022120916075589200_hem2022000341C11","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1182\/blood-2014-05-579136","article-title":"Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis","volume":"124","author":"Tefferi","year":"2014","journal-title":"Blood"},{"issue":"21","key":"2022120916075589200_hem2022000341C12","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.1182\/blood-2014-10-608315","article-title":"Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis","volume":"125","author":"Kr\u00f6ger","year":"2015","journal-title":"Blood"},{"issue":"10","key":"2022120916075589200_hem2022000341C13","doi-asserted-by":"crossref","first-page":"873.e1","DOI":"10.1016\/j.jtct.2021.05.016","article-title":"Outcomes of allogeneic hematopoietic cell transplantation in patients with myelofibrosis\u2014a systematic review and meta-analysis","volume":"27","author":"Bewersdorf","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"15","key":"2022120916075589200_hem2022000341C14","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1182\/blood-2010-06-293415","article-title":"Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis","volume":"116","author":"Passamonti","year":"2010","journal-title":"Blood"},{"issue":"4","key":"2022120916075589200_hem2022000341C15","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1200\/JCO.2017.76.4886","article-title":"MIPSS70: Mutation-Enhanced International Prognostic Score System for transplantation-age patients with primary myelofibrosis","volume":"36","author":"Guglielmelli","year":"2018","journal-title":"J Clin Oncol"},{"issue":"3","key":"2022120916075589200_hem2022000341C16","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/hon.2737","article-title":"Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: real-world data","volume":"38","author":"Palandri","year":"2020","journal-title":"Hematol Oncol"},{"issue":"7","key":"2022120916075589200_hem2022000341C17","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1038\/s41375-018-0107-z","article-title":"GIPSS: Genetically Inspired Prognostic Scoring System for primary myelofibrosis","volume":"32","author":"Tefferi","year":"2018","journal-title":"Leukemia"},{"issue":"4","key":"2022120916075589200_hem2022000341C18","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1182\/bloodadvances.2018015875","article-title":"Targeted next-generation sequencing in blast phase myeloproliferative neoplasms","volume":"2","author":"Lasho","year":"2018","journal-title":"Blood Adv"},{"issue":"17","key":"2022120916075589200_hem2022000341C19","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1200\/JCO.2011.34.7542","article-title":"Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms","volume":"29","author":"Bj\u00f6rkholm","year":"2011","journal-title":"J Clin Oncol"},{"issue":"4, pt 2","key":"2022120916075589200_hem2022000341C20","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1055\/s-2006-942762","article-title":"Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia","volume":"32","author":"Kiladjian","year":"2006","journal-title":"Semin Thromb Hemost"},{"issue":"2","key":"2022120916075589200_hem2022000341C21","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1182\/bloodadvances.2016000208","article-title":"Targeted deep sequencing in primary myelofibrosis","volume":"1","author":"Tefferi","year":"2016","journal-title":"Blood Adv"},{"issue":"50","key":"2022120916075589200_hem2022000341C22","doi-asserted-by":"crossref","first-page":"E5401","DOI":"10.1073\/pnas.1407792111","article-title":"Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms","volume":"111","author":"Rampal","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"issue":"19","key":"2022120916075589200_hem2022000341C23","doi-asserted-by":"crossref","first-page":"4480","DOI":"10.1182\/blood-2011-11-390252","article-title":"Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome","volume":"119","author":"Zhang","year":"2012","journal-title":"Blood"},{"issue":"23","key":"2022120916075589200_hem2022000341C24","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N Engl J Med"},{"issue":"2","key":"2022120916075589200_hem2022000341C25","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41375-018-0357-9","article-title":"Targeting FLT3 mutations in AML: review of current knowledge and evidence","volume":"33","author":"Daver","year":"2019","journal-title":"Leukemia"},{"issue":"14","key":"2022120916075589200_hem2022000341C26","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1182\/blood-2013-11-537167","article-title":"Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms","volume":"123","author":"Lundberg","year":"2014","journal-title":"Blood"},{"issue":"7834","key":"2022120916075589200_hem2022000341C27","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/s41586-020-2864-x","article-title":"Single-cell mutation analysis of clonal evolution in myeloid malignancies","volume":"587","author":"Miles","year":"2020","journal-title":"Nature"},{"issue":"7","key":"2022120916075589200_hem2022000341C28","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa1412098","article-title":"Effect of mutation order on myeloproliferative neoplasms","volume":"372","author":"Ortmann","year":"2015","journal-title":"N Engl J Med"},{"issue":"9","key":"2022120916075589200_hem2022000341C29","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1182\/bloodadvances.2021005867","article-title":"Single-cell analysis reveals selection of TP53-mutated clones after MDM2 inhibition","volume":"6","author":"Maslah","year":"2022","journal-title":"Blood Adv"},{"key":"2022120916075589200_hem2022000341C30","article-title":"Deciphering TP53 mutant cancer evolution with single-cell multi-omics. Preprint","author":"Rodriguez-Meira","year":"2022","journal-title":"bioRxiv"},{"issue":"September","key":"2022120916075589200_hem2022000341C31","doi-asserted-by":"crossref","first-page":"100947","DOI":"10.1016\/j.blre.2022.100947","article-title":"Addressing the challenges of accelerated and blast phase myeloproliferative neoplasms in 2022 and beyond","volume":"55","author":"Saha","year":"2022","journal-title":"Blood Rev"},{"issue":"suppl 1","key":"2022120916075589200_hem2022000341C32","doi-asserted-by":"crossref","first-page":"100711","DOI":"10.1016\/j.blre.2020.100711","article-title":"Role of inflammation in the biology of myeloproliferative neoplasms","volume":"42","author":"Koschmieder","year":"2020","journal-title":"Blood Rev"},{"issue":"19","key":"2022120916075589200_hem2022000341C33","doi-asserted-by":"crossref","first-page":"4748","DOI":"10.1182\/bloodadvances.2020002621","article-title":"Comparison of outcomes of HCT in blast phase of BCR-ABL1\u2212 MPN with de novo AML and with AML following MDS","volume":"4","author":"Gupta","year":"2020","journal-title":"Blood Adv"},{"issue":"21","key":"2022120916075589200_hem2022000341C34","doi-asserted-by":"crossref","first-page":"5562","DOI":"10.1182\/bloodadvances.2020002727","article-title":"Genetic factors rather than blast reduction determine outcomes of allogeneic HCT in BCR-ABL- negative MPN in blast phase","volume":"4","author":"Gupta","year":"2020","journal-title":"Blood Adv"},{"issue":"6","key":"2022120916075589200_hem2022000341C35","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/bmt.2014.31","article-title":"Allo-SCT for Philadelphia-negative myeloproliferative neoplasms in blast phase: a study from the Societe Fran\u00e7aise de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC)","volume":"49","author":"Cahu","year":"2014","journal-title":"Bone Marrow Transpl"},{"issue":"2","key":"2022120916075589200_hem2022000341C36","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.bbmt.2013.10.027","article-title":"Allogeneic stem cell transplantation for myelofibrosis with leukemic transformation: a study from the Myeloproliferative Neoplasm Subcommittee of the CMWP of the European Group for Blood and Marrow Transplantation","volume":"20","author":"Alchalby","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"14","key":"2022120916075589200_hem2022000341C37","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.1182\/blood-2012-10-464248","article-title":"Treatment outcomes following leukemic transformation in Philadelphia-negative myeloproliferative neoplasms","volume":"121","author":"Kennedy","year":"2013","journal-title":"Blood"},{"issue":"3","key":"2022120916075589200_hem2022000341C38","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","article-title":"Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study","volume":"10","author":"Fenaux","year":"2009","journal-title":"Lancet Oncol"},{"issue":"4","key":"2022120916075589200_hem2022000341C39","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1200\/JCO.2009.23.8329","article-title":"Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia","volume":"28","author":"Fenaux","year":"2010","journal-title":"J Clin Oncol"},{"issue":"8","key":"2022120916075589200_hem2022000341C40","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1002\/cncr.21792","article-title":"Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study","volume":"106","author":"Kantarjian","year":"2006","journal-title":"Cancer"},{"issue":"9","key":"2022120916075589200_hem2022000341C41","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.leukres.2015.06.001","article-title":"Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic\/acute myeloid leukemia phase","volume":"39","author":"Badar","year":"2015","journal-title":"Leuk Res"},{"issue":"8","key":"2022120916075589200_hem2022000341C42","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.leukres.2015.03.001","article-title":"Azacytidine for the treatment of retrospective analysis from the Gruppo Laziale for the study of Ph-negative MPN","volume":"39","author":"Andriani","year":"2015","journal-title":"Leuk Res"},{"issue":"3","key":"2022120916075589200_hem2022000341C43","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/hon.2635","article-title":"Treatment of Philadelphia-negative myeloproliferative neoplasms in accelerated\/blastic phase with azacytidine: clinical results and identification of prognostic factors","volume":"37","author":"Andriani","year":"2019","journal-title":"Hematol Oncol"},{"issue":"7","key":"2022120916075589200_hem2022000341C44","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1002\/ajh.26186","article-title":"Venetoclax with azacitidine or decitabine in blast-phase myeloproliferative neoplasm: a multicenter series of 32 consecutive cases","volume":"96","author":"Gangat","year":"2021","journal-title":"Am J Hematol"},{"issue":"8","key":"2022120916075589200_hem2022000341C45","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1182\/bloodadvances.2020003934","article-title":"Single-center experience with venetoclax combinations in patients with newly diagnosed and relapsed AML evolving from MPNs","volume":"5","author":"Masarova","year":"2021","journal-title":"Blood Adv"},{"issue":"11","key":"2022120916075589200_hem2022000341C46","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.3324\/haematol.2019.242826","article-title":"Venetoclax as monotherapy and in combination with hypomethylating agents or low dose cytarabine in relapsed and treatment refractory acute myeloid leukemia: a systematic review and meta-analysis","volume":"105","author":"Bewersdorf","year":"2020","journal-title":"Haematologica"},{"issue":"1","key":"2022120916075589200_hem2022000341C47","doi-asserted-by":"crossref","first-page":"E7","DOI":"10.1002\/ajh.26381","article-title":"Multicenter evaluation of efficacy and toxicity of venetoclax-based combinations in patients with accelerated and blast phase myeloproliferative neoplasms","volume":"97","author":"King","year":"2022","journal-title":"Am J Hematol"},{"issue":"20","key":"2022120916075589200_hem2022000341C48","doi-asserted-by":"crossref","first-page":"4614","DOI":"10.1182\/blood-2011-12-400051","article-title":"Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia","volume":"119","author":"Eghtedar","year":"2012","journal-title":"Blood"},{"issue":"20","key":"2022120916075589200_hem2022000341C49","doi-asserted-by":"crossref","first-page":"5246","DOI":"10.1182\/bloodadvances.2020002119","article-title":"Phase 2 study of ruxolitinib and decitabine in patients with myeloproliferative neoplasm in accelerated and blast phase","volume":"4","author":"Mascarenhas","year":"2020","journal-title":"Blood Adv"},{"issue":"9","key":"2022120916075589200_hem2022000341C50","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1038\/s41375-020-0778-0","article-title":"A phase \u00bd study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia","volume":"34","author":"Bose","year":"2020","journal-title":"Leukemia"},{"issue":"suppl 1","key":"2022120916075589200_hem2022000341C51","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1182\/blood-2021-153071","article-title":"Navtemadlin (KRT-232), a small molecule MDM2 inhibitor, is more effective than decitabine against myeloproliferative neoplasm-blast phase in a patient-derived xenograft model","volume":"138","author":"Wang","year":"2021","journal-title":"Blood"},{"issue":"3","key":"2022120916075589200_hem2022000341C52","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/leu.2016.260","article-title":"BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells","volume":"31","author":"Saenz","year":"2017","journal-title":"Leukemia"},{"issue":"21","key":"2022120916075589200_hem2022000341C53","doi-asserted-by":"crossref","first-page":"5336","DOI":"10.1182\/bloodadvances.2020001528","article-title":"Outcome of patients with IDH1\/2-mutated post\u2013myeloproliferative neoplasm AML in the era of IDH inhibitors","volume":"4","author":"Chifotides","year":"2020","journal-title":"Blood Adv"},{"issue":"1","key":"2022120916075589200_hem2022000341C54","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1111\/bjh.16709","article-title":"Clinical outcomes of IDH2- mutated advanced-phase Ph-negative myeloproliferative neoplasms treated with enasidenib","volume":"190","author":"Patel","year":"2020","journal-title":"Br J Haematol"},{"issue":"4","key":"2022120916075589200_hem2022000341C55","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"issue":"12","key":"2022120916075589200_hem2022000341C56","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1016\/j.leukres.2012.08.013","article-title":"Proposed criteria for response assessment in patients treated in clinical trials for myeloproliferative neoplasms in blast phase (MPN-BP): formal recommendations from the post-myeloproliferative neoplasm acute myeloid leukemia consortium","volume":"36","author":"Mascarenhas","year":"2012","journal-title":"Leuk Res"},{"issue":"November","key":"2022120916075589200_hem2022000341C57","doi-asserted-by":"crossref","first-page":"e366","DOI":"10.1038\/bcj.2015.95","article-title":"Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors","volume":"5","author":"Cerquozzi","year":"2015","journal-title":"Blood Cancer J"},{"issue":"9","key":"2022120916075589200_hem2022000341C58","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1038\/leu.2013.163","article-title":"Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study","volume":"27","author":"Tefferi","year":"2013","journal-title":"Leukemia"},{"issue":"33","key":"2022120916075589200_hem2022000341C59","doi-asserted-by":"crossref","first-page":"5587","DOI":"10.1200\/JCO.2009.22.8833","article-title":"Dynamic model for predicting death within 12 months in patients with primary or post\u2013polycythemia vera\/essential thrombocythemia myelofibrosis","volume":"27","author":"Tam","year":"2009","journal-title":"J Clin Oncol"},{"issue":"5","key":"2022120916075589200_hem2022000341C60","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1111\/bjh.14762","article-title":"Impact of genotype on leukaemic transformation in polycythaemia vera and essential thrombocythaemia","volume":"178","author":"Alvarez-Larr\u00e1n","year":"2017","journal-title":"Br J Haematol"},{"issue":"12","key":"2022120916075589200_hem2022000341C61","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1080\/10428194.2018.1441408","article-title":"Outcome of Ph negative myeloproliferative neoplasms transforming to accelerated or leukemic phase","volume":"59","author":"Mollard","year":"2018","journal-title":"Leuk Lymphoma"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2022\/1\/218\/2021697\/218bewersdorf.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2022\/1\/218\/2021697\/218bewersdorf.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T16:09:41Z","timestamp":1670602181000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2022\/1\/218\/493497\/Hitting-the-brakes-on-accelerated-and-blast-phase"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,9]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12,9]]},"published-print":{"date-parts":[[2022,12,9]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2022000341","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,12,9]]},"published":{"date-parts":[[2022,12,9]]}}}